No Data
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline Including Advancements With High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile. KSI-501 clinical and non-clinical data hig
BGC, DRS and AMTX Are Among After Hour Movers
Kodiak Sciences Is Maintained at Neutral by UBS
Kodiak Sciences Is Maintained at Neutral by UBS
UBS Maintains Neutral on Kodiak Sciences, Raises Price Target to $5
UBS analyst Eliana Merle maintains Kodiak Sciences (NASDAQ:KOD) with a Neutral and raises the price target from $3 to $5.
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersAesthetic Medical Intl (NASDAQ:AIH) shares rose 14.0% to $0.52 during Wednesday's after-market session. The company's market cap stands at $24.9 million. Kineta (NASDAQ:KA) shares rose 8.46% to
Kodiak Sciences Inc. (NASDAQ:KOD) Q4 2023 Earnings Call Transcript